NSPR · InspireMD, Inc.

InspireMD's voluntary recall of the CGuard Prime 135 cm carotid stent delivery system stems from technical performance shortfalls identified during a controlled U.S. launch, prompting a proactive pause in commercialization to implement design enhancements. This action, taken in consultation with the FDA, isolates the issue to the delivery system without implicating patient safety or the core CGuard stent implant, which maintains its strong clinical profile with lowest major adverse event rates in CAS. Despite the disruption, Q1 2026 demonstrated robust demand with 53% global year-over-year and 34% U.S. quarter-over-quarter unit sales growth, underscoring the technology's appeal. The recall's impact led to the withdrawal of full-year 2026 revenue guidance, reflecting prudent management amid anticipated Q3 2026 FDA approval for the original CGuard delivery system, proven in over 70,000 worldwide cases. Positively, FDA approval of the IDE for the CGUARDIANS III pivotal study advances the SwitchGuard neuroprotection system paired with CGuard Prime 80 cm for TCAR, targeting a market of ~35,000 annual U.S. procedures that could double addressable opportunity. With CGuard Prime 80 cm meeting expectations and on track for 2H 2026 approval, plus SwitchGuard clearance eyed for 2H 2027, these developments signal continued pipeline progress amid the near-term U.S. setback. Investors should monitor Q1 results call on May 4, 2026, for updated outlook and remediation costs.